Drug interactions
Indacaterol-glycopyrronium + Umeclidinium bromide / vilanterol inhaled
Severity: Major
Indacaterol-glycopyrronium and Umeclidinium bromide / vilanterol inhaled: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both products combine a long-acting beta2-agonist with a long-acting muscarinic antagonist, so using them together is therapeutic duplication. The combined exposure increases the risk of tachycardia, palpitations, hypokalemia, dry mouth and urinary retention without added benefit.
What this interaction means in plain words
Indacaterol-glycopyrronium and Umeclidinium bromide / vilanterol inhaled can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
Additive beta2-adrenergic stimulation and muscarinic receptor blockade from duplicate LABA and LAMA components.
What to do
Do not use both inhalers together; select a single LABA/LAMA product. Monitor cardiovascular status and potassium if overlap has occurred.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Indacaterol-glycopyrronium and Umeclidinium bromide / vilanterol inhaled, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Indacaterol-glycopyrronium
Frequently asked questions
Can I take Indacaterol-glycopyrronium with Umeclidinium bromide / vilanterol inhaled?
MediHelp rates the interaction as major. Indacaterol-glycopyrronium and Umeclidinium bromide / vilanterol inhaled can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both products combine a long-acting beta2-agonist with a long-acting muscarinic antagonist, so using them together is therapeutic duplication. The combined exposure increases the risk of tachycardia, palpitations, hypokalemia, dry mouth and urinary retention without added benefit.
How serious is the interaction between Indacaterol-glycopyrronium and Umeclidinium bromide / vilanterol inhaled?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Do not use both inhalers together; select a single LABA/LAMA product. Monitor cardiovascular status and potassium if overlap has occurred.
What other medicines interact with Indacaterol-glycopyrronium?
MediHelp also lists interactions of Indacaterol-glycopyrronium with, for example, Amisulpride, Arformoterol, Arsenic trioxide. The full list is on the Indacaterol-glycopyrronium page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
